Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology.

作者
Thierry Lequerré,Olivier Vittecoq,Nathalie Klemmer,Vincent Goëb,Sophie Pouplin,Jean-François Ménard,A Daragon,Othmane Mejjad,Xavier Le Loët
出处
期刊:PubMed [National Institutes of Health]
卷期号:33 (7): 1307-14 被引量:49
链接
标识
摘要

OBJECTIVE: To suggest recommendations for management of acute infusion reactions induced by infliximab in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA). METHODS: In total, 203 patients were treated with infliximab (120 ml/h). Prevalence of acute infusion reaction was evaluated. To manage these conditions, recommendations were devised according to the type and the severity of clinical manifestations, which were classified beforehand in 2 groups: A (hypertension, pruritus, sudden flush, vomiting, tachycardia or bradycardia, shivers, fever) and B (urticaria, tickling throat, Quincke's edema, dyspnea, and hypotension). Recommendations were based mainly on adjustment of the infusion rate. RESULTS: It was observed that 23/203 patients (11.3%) had acute infusion reactions. Among them and prior to our recommendations, infliximab was completely discontinued in 8/23 patients. After our recommendations were implemented, 15/23 patients presented an acute infusion reaction: 8 and 7 patients with symptoms of Group A and B, respectively. In Group A (8 patients), reducing the infusion rate to 60-80 ml/h led to disappearance of symptoms; the modified treatment was then maintained. In Group B (7 patients), the infusion was immediately stopped and appropriate drugs were administered. Once clinical manifestations were alleviated, the infusion was resumed (60 ml/h). Prior to subsequent infusions (60 ml/h), a premedication was administered. CONCLUSION: Based on these recommendations, infliximab could be maintained with great efficacy on disease activity in every patient with an acute infusion reaction. Our recommendations permit sustained administration of infliximab and allow every patient to benefit from this therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
未来完成签到 ,获得积分10
4秒前
星宇完成签到 ,获得积分10
7秒前
星辰大海的应助被Brave采纳,获得10
8秒前
隐形期待完成签到,获得积分10
12秒前
陶醉静竹发布了新的文献求助10
13秒前
zhao完成签到,获得积分10
13秒前
小墨墨完成签到 ,获得积分10
16秒前
锂电说完成签到 ,获得积分10
18秒前
18秒前
独指蜗牛完成签到 ,获得积分10
19秒前
Brave完成签到,获得积分10
20秒前
maclogos完成签到,获得积分10
23秒前
Brave发布了新的文献求助10
23秒前
李希完成签到 ,获得积分10
25秒前
阿俊1212完成签到 ,获得积分10
25秒前
chenpy1990完成签到 ,获得积分10
27秒前
科研菜鸡完成签到 ,获得积分10
27秒前
佳言2009完成签到 ,获得积分10
28秒前
小丽酱完成签到 ,获得积分10
29秒前
zz6532完成签到 ,获得积分10
32秒前
漂亮夏兰完成签到 ,获得积分10
33秒前
旺旺雪饼完成签到 ,获得积分10
33秒前
友好沛槐完成签到,获得积分10
40秒前
47秒前
之昂完成签到 ,获得积分10
48秒前
漂亮忆曼完成签到,获得积分10
50秒前
Flora完成签到 ,获得积分10
52秒前
shg完成签到,获得积分10
54秒前
豆豆发布了新的文献求助10
54秒前
hikc完成签到 ,获得积分10
56秒前
懒猫完成签到,获得积分10
58秒前
我是老大的应助被科研通管家采纳,获得10
58秒前
cssc完成签到,获得积分10
58秒前
彩色从雪完成签到 ,获得积分10
1分钟前
小耳朵完成签到 ,获得积分10
1分钟前
aRuuuu完成签到 ,获得积分10
1分钟前
江水边完成签到 ,获得积分10
1分钟前
仰望星空jiang完成签到,获得积分10
1分钟前
1分钟前
safeandsound完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180068
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808724
捐赠科研通 7776054
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557425
邀请新用户注册赠送积分活动 2479012